Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Erbitux timeline not addressed at IMCL meeting

ImClone (IMCL) President and CEO Harlan Waksal said in his prepared comments at the company's annual shareholder meeting that

Read the full 198 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE